Japan aims toward appropriate concomitant use of antiplatelets and antisecretory agents?
Fujishiro
Mitsuhiro
M
D054058:Acute Coronary Syndrome / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D023903:Coronary Restenosis / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D016481:Helicobacter Infections / Q000453:epidemiology; D006635:Histamine H2 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015995:Prevalence; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors
D006635:Histamine H2 Antagonists; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors